Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Teva Pharmaceutical Industries continues to divest products to satisfy antitrust regulators assessing its planned acquisition of Allergan’s generic drug business. Impax Laboratories will pay $586 million for 15 marketed generics plus the rights to products not yet launched and to the pending Abbreviated New Drug Application (ANDA) for the generic equivalent of Concerta, a product on which the two companies collaborated. Sagent Pharmaceuticals, meanwhile, will pay $40 million for five ANDAs pending in the U.S. Earlier this month, Teva sold a raft of ANDAs to Dr. Reddy’s Laboratories.
This article has been sent to the following recipient: